BioCentury | Jun 4, 2020
Finance

Everest to fund late-stage trials with $310M mountain of fresh cash

A new $310 million series C round for Everest is the largest venture round yet for an Asian therapeutics developer, and could set the cross-border licensing and development company up for an IPO at a...
BioCentury | May 14, 2020
Emerging Company Profile

Kriya emerges with $80.5M A round, three gene therapies for diabetes and obesity

A team of gene therapy veterans from the likes of Sangamo, Spark and AveXis have debuted Kriya with an untranched $80.5 million series A round to bring gene therapies to patients with prevalent and severe...
BC Innovations | Dec 20, 2019
Product Development

Pharma spinouts: a snapshot of where and how pharmas spin out their assets

The handoff of innovation to academia is all but complete, with universities and other academic institutions accounting for the origin of about 75% of new companies formed in the last three years. But while pharma...
BC Extra | Sep 11, 2019
Company News

Sept. 11 Company Quick Takes: Glaxo to buy Sitari; plus Aimmune, Xeris, Puma and United Therapeutics

GSK acquires celiac company Sitari  GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) is acquiring Sitari Pharmaceuticals Inc. (La Jolla, Calif.), the first company formed and funded under a 2013 build-to-buy partnership between Avalon Ventures and the pharma. Financial...
BioCentury | Jul 26, 2019
Finance

Earnings on deck

Earnings on deck At least 27 profitable biotechs and pharmas are slated to report earnings this week. (A) During market hours in Europe, premarket on U.S. exchanges; (B) Fiscal 1Q Company Date Pre/post mkt 2Q19...
BC Extra | Jul 1, 2019
Company News

Management Tracks: BioCryst hires its first CBO; plus ObsEva, Veracyte and more

Rare disease company BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) hired Megan Sniecinski as its first CBO. She was SVP of business operations and program management at PTC Therapeutics Inc. (NASDAQ:PTCT). Reproductive health company ObsEva S.A. (NASDAQ:OBSV; SIX:OBSN)...
BC Extra | Apr 26, 2019
Company News

Amgen, Astellas join list of biopharmas paying for alleged co-pay charity kickbacks

The Department of Justice said Thursday that Amgen and Astellas have agreed to pay $124.8 million combined to settle allegations of kickbacks to charitable patient assistance programs. Astellas Pharma Inc. (Tokyo:4503) will pay $100 million...
BioCentury | Apr 26, 2019
Finance

Earnings on deck

Earnings on deck At least 17 profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 2Q; (B) During trading hours in Europe; premarket on U.S. exchange Company Date Pre/post mkt 1Q19...
BC Extra | Apr 8, 2019
Clinical News

United Therapeutics' esuberaprost fails Phase III in PAH

United Therapeutics discontinued development of esuberaprost after the compound failed to meet the primary endpoint in the Phase III BEAT trial to treat pulmonary arterial hypertension. Esuberaprost is a single isomer formulation of beraprost, a...
BC Extra | Apr 5, 2019
Politics & Policy

DOJ releases details on biopharma settlements for alleged kickbacks to co-pay charities

Alexion has been added to the list of biopharma companies that have settled allegations of kickbacks to charitable patient assistance programs, according to a Department of Justice statement released Thursday. United Therapeutics Corp. (NASDAQ:UTHR), Actelion...
Items per page:
1 - 10 of 611
BioCentury | Jun 4, 2020
Finance

Everest to fund late-stage trials with $310M mountain of fresh cash

A new $310 million series C round for Everest is the largest venture round yet for an Asian therapeutics developer, and could set the cross-border licensing and development company up for an IPO at a...
BioCentury | May 14, 2020
Emerging Company Profile

Kriya emerges with $80.5M A round, three gene therapies for diabetes and obesity

A team of gene therapy veterans from the likes of Sangamo, Spark and AveXis have debuted Kriya with an untranched $80.5 million series A round to bring gene therapies to patients with prevalent and severe...
BC Innovations | Dec 20, 2019
Product Development

Pharma spinouts: a snapshot of where and how pharmas spin out their assets

The handoff of innovation to academia is all but complete, with universities and other academic institutions accounting for the origin of about 75% of new companies formed in the last three years. But while pharma...
BC Extra | Sep 11, 2019
Company News

Sept. 11 Company Quick Takes: Glaxo to buy Sitari; plus Aimmune, Xeris, Puma and United Therapeutics

GSK acquires celiac company Sitari  GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) is acquiring Sitari Pharmaceuticals Inc. (La Jolla, Calif.), the first company formed and funded under a 2013 build-to-buy partnership between Avalon Ventures and the pharma. Financial...
BioCentury | Jul 26, 2019
Finance

Earnings on deck

Earnings on deck At least 27 profitable biotechs and pharmas are slated to report earnings this week. (A) During market hours in Europe, premarket on U.S. exchanges; (B) Fiscal 1Q Company Date Pre/post mkt 2Q19...
BC Extra | Jul 1, 2019
Company News

Management Tracks: BioCryst hires its first CBO; plus ObsEva, Veracyte and more

Rare disease company BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) hired Megan Sniecinski as its first CBO. She was SVP of business operations and program management at PTC Therapeutics Inc. (NASDAQ:PTCT). Reproductive health company ObsEva S.A. (NASDAQ:OBSV; SIX:OBSN)...
BC Extra | Apr 26, 2019
Company News

Amgen, Astellas join list of biopharmas paying for alleged co-pay charity kickbacks

The Department of Justice said Thursday that Amgen and Astellas have agreed to pay $124.8 million combined to settle allegations of kickbacks to charitable patient assistance programs. Astellas Pharma Inc. (Tokyo:4503) will pay $100 million...
BioCentury | Apr 26, 2019
Finance

Earnings on deck

Earnings on deck At least 17 profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 2Q; (B) During trading hours in Europe; premarket on U.S. exchange Company Date Pre/post mkt 1Q19...
BC Extra | Apr 8, 2019
Clinical News

United Therapeutics' esuberaprost fails Phase III in PAH

United Therapeutics discontinued development of esuberaprost after the compound failed to meet the primary endpoint in the Phase III BEAT trial to treat pulmonary arterial hypertension. Esuberaprost is a single isomer formulation of beraprost, a...
BC Extra | Apr 5, 2019
Politics & Policy

DOJ releases details on biopharma settlements for alleged kickbacks to co-pay charities

Alexion has been added to the list of biopharma companies that have settled allegations of kickbacks to charitable patient assistance programs, according to a Department of Justice statement released Thursday. United Therapeutics Corp. (NASDAQ:UTHR), Actelion...
Items per page:
1 - 10 of 611